Abstract
Prevalent copy number alteration is the most prominent genetic characteristic associated with ovarian cancer (OV) development, but its role in immune evasion has not been fully elucidated. In this study, we identified RAD21, a key component of the cohesin complex, as a frequently amplified oncogene that could modulate immune response in OV. Through interrogating the RAD21-regulated transcriptional program, we found that RAD21 directly interacts with YAP/TEAD4 transcriptional corepressors and recruits the NuRD complex to suppress interferon (IFN) signaling. In multiple clinical cohorts, RAD21 overexpression is inversely correlated with IFN signature gene expression in OV. We further demonstrated in murine syngeneic tumor models that RAD21 ablation potentiated anti-PD-1 efficacy with increased intratumoral CD8+ T cell effector activity. Our study identifies a RAD21-YAP/TEAD4-NuRD corepressor complex in immune modulation, and thus provides a potential target and biomarker for precision immunotherapy in OV.
Introduction
High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecological malignancy, primarily due to late-stage presentation and a high rate of resistance to conventional therapies. While immune checkpoint blockade (ICB) has revolutionized treatment for various solid tumors, its success in HGSOC has been notably limited. A hallmark of HGSOC is the presence of extensive copy number alterations (CNAs), yet the specific mechanisms by which these genomic changes facilitate immune evasion have remained poorly understood. This study identifies RAD21 as a critical oncogenic driver that actively suppresses the host immune response through epigenetic silencing.
Methods
To investigate the role of RAD21, researchers utilized a multi-omic approach:
- Genomic Screening: Analysis of TCGA-OV and Gene Expression Omnibus (GSE69428) datasets identified genes frequently amplified and overexpressed in HGSOC.
- Functional Assays: siRNA/shRNA knockdown and CRISPR/Cas9 knockout models were used to evaluate the impact of RAD21 on tumor growth and immune signaling pathways.
- Epigenetic Mapping: RNA-Seq and ChIP-Seq (targeting RAD21 and H3K27ac) were performed to define the RAD21-regulated transcriptome and its epigenetic landscape.
- Protein Interaction Studies: Co-immunoprecipitation and confocal microscopy were employed to identify the RAD21-YAP/TEAD4-NuRD corepressor complex.
- Preclinical Evaluation: Syngeneic mouse models (B16-OVA and ID8) were used to test the therapeutic potential of targeting RAD21 in combination with anti-PD-1 therapy.
Results
RAD21 is Frequently Amplified in HGSOC
Genomic analysis revealed that RAD21 is amplified in approximately 21% of HGSOC patients, representing the most frequent amplification event in this disease. This amplification leads to a significant increase in RAD21 expression levels compared to normal tissue.
Epigenetic Suppression of the Interferon Response
Mechanistically, RAD21 was found to act as a transcriptional repressor by recruiting the YAP/TEAD4 and NuRD complexes to the promoters of interferon-stimulated genes (ISGs). This complex removes active H3K27ac marks, thereby silencing the interferon signaling pathway—a critical "alarm system" for attracting T cells to the tumor microenvironment. This creates a "cold" immune environment that allows the tumor to evade detection.
Clinical Significance and Therapeutic Synergy
High expression of RAD21 is strongly associated with poor clinical outcomes, including significantly reduced overall survival and increased recurrence rates.
In vivo studies demonstrated that ablating RAD21 increases intratumoral CD8+ T cell infiltration and MHC-I expression. Furthermore, combining RAD21 loss with anti-PD-1 therapy significantly reduced tumor volume and improved survival in mouse models, highlighting RAD21 as a promising target for enhancing immunotherapy efficacy.
Discussion
This study identifies a novel role for RAD21 as a molecular silencer of anti-tumor immunity. By epigenetically suppressing interferon signaling, RAD21 amplification enables ovarian tumors to bypass immune surveillance. While RAD21 is essential for chromosome organization, targeting its specific interaction with the YAP/TEAD4-NuRD complex may offer a way to sensitize tumors to immunotherapy without the toxicity associated with global cohesin inhibition. These findings establish RAD21 as both a potential therapeutic target and a valuable biomarker for precision medicine in ovarian cancer.
Summary updated